Diffuse large B-cell lymphoma (DLBCL) is identified in the PubMed record as the most common subtype of non-Hodgkin lymphoma and is characterized by high aggressiveness and rapid tumor growth. The article title and opening lines indicate the study focuses on an anticancer natural compound, Erianin, derived from the herb Dendrobium, in the context of DLBCL.
The PubMed entry title states that Erianin induces GSDMD-dependent pyroptosis and that it synergistically enhances doxorubicin efficacy via the PI3K/AKT signaling pathway in DLBCL. These claims are presented in the article title as the primary findings. The provided PubMed excerpt does not include the full abstract, methods, results, or conclusions necessary to evaluate or quantify these reported effects.
The citation lists Hanwei Mei and multiple coauthors. Affiliations provided in the PubMed record include:
These institutional details are reported in the PubMed entry and may assist readers seeking author contact or institutional context.
The PubMed record provides bibliographic identifiers that permit retrieval of the full manuscript: PMID 40830921 and DOI 10.1097/CM9.0000000000003634. The article is listed in Chin Med J (Engl), with Epub date 2025 Aug 20 and journal issue metadata 2026 Sep 20;139(18):2808-2820.
The provided PubMed content includes only the opening fragment of the abstract. The abstract is truncated in the source material supplied here, stopping after an introductory sentence that states erianin has shown anticancer effects in certain cancers and that the compound's role and mechanistic details in DLBCL were under investigation. The Methods, Results, and Conclusions sections of the abstract are not included in the supplied source. Therefore, experimental details and outcome data are unavailable in this record excerpt.
From the available title and opening abstract line, the PubMed record confirms the intended investigational scope: evaluation of Erianin in DLBCL with attention to induction of GSDMD-dependent pyroptosis, interaction with the anthracycline doxorubicin, and involvement of the PI3K/AKT signaling pathway. The title asserts synergy between erianin and doxorubicin and implicates a specific cell-death mechanism (GSDMD-dependent pyroptosis) and signaling axis (PI3K/AKT). However, precise experimental systems (cell lines, animal models), methods (biochemical assays, genetic manipulation), and quantitative results are not present in the excerpt.
The supplied PubMed excerpt does not report:
Because these elements are not present in the provided source, they cannot be summarized or interpreted here.
To evaluate the study fully, readers should retrieve the complete article via the DOI (10.1097/CM9.0000000000003634) or through the journal Chin Med J (Engl). The PubMed entry includes full-text links that can be used to obtain the Methods, Results, figures, and Discussion sections. Accessing the full text is necessary to appraise the experimental validity, reproducibility, clinical relevance, and potential translational implications of the claims that erianin induces GSDMD-dependent pyroptosis and enhances doxorubicin efficacy through PI3K/AKT modulation in DLBCL.
Note: This summary is based solely on the PubMed record content provided. The abstract and article body were truncated in the supplied source, so experimental results, numerical data, and conclusions reported in the full paper are not available here and are not inferred or synthesized beyond what the record explicitly states.